Contact
searchSearch
HMP Global

Diffuse Large B-Cell Lymphoma Resource Center

Diffuse Large B-Cell Lymphoma
Learning Library

New & Trending

EZH2
Rapid Refresh
Understanding the Role of EZH2 in Cancer Pathogenesis
02/28/2024
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role...
02/28/2024
APP Institute Oncology
Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
From Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
From Oncology

Clinical Pearls

EZH2
Rapid Refresh
Understanding the Role of EZH2 in Cancer Pathogenesis
02/28/2024
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role...
02/28/2024
APP Institute Oncology
Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Conference Coverage
Biological Pathways Underlying Cancer-Related Cognitive Impairment and Anxiety in Patients Receiving Chemotherapy
04/10/2025
Janelle Bradley
A new study has identified both shared and distinct biological mechanisms underlying cancer-related cognitive impairment and anxiety in patients undergoing chemotherapy.
A new study has identified both shared and distinct biological mechanisms underlying cancer-related cognitive impairment and anxiety in patients undergoing chemotherapy.
A new study has identified both...
04/10/2025
APP Institute Oncology
Conference Coverage
Epigenetic Insights Reveal Distinct Pathways Underlying Cognitive Function in Patients With Early-Stage Breast Cancer
04/10/2025
Janelle Bradley
Epigenetic analysis in postmenopausal women with early-stage breast cancer reveals distinct biological pathways—axonal guidance and synaptogenesis—underlying objective and subjective cognitive function, suggesting separate mechanisms driving...
Epigenetic analysis in postmenopausal women with early-stage breast cancer reveals distinct biological pathways—axonal guidance and synaptogenesis—underlying objective and subjective cognitive function, suggesting separate mechanisms driving...
Epigenetic analysis in...
04/10/2025
APP Institute Oncology
Conference Coverage
Barriers and Drivers of Symptom Self-Management in Rural Cancer Survivors
04/10/2025
Janelle Bradley
Study defines factors that shape rural cancer survivors’ use of symptom self-management strategies, including credibility, symptom severity, accessibility, personal preferences, and social support.
Study defines factors that shape rural cancer survivors’ use of symptom self-management strategies, including credibility, symptom severity, accessibility, personal preferences, and social support.
Study defines factors that shape...
04/10/2025
APP Institute Oncology
Anne Mailhot, PA-C, University of Colorado Cancer Center
Videos
Management of a Patient With GIST and KIT Mutations
04/07/2025
Anne Mailhot, PA-C, presents the case of a patient with gastrointestinal stromal tumor with mutations in the KIT gene.
Anne Mailhot, PA-C, presents the case of a patient with gastrointestinal stromal tumor with mutations in the KIT gene.
Anne Mailhot, PA-C, presents the...
04/07/2025
APP Institute Oncology
News
Incidence and Predictors of Obinutuzumab Infusion-Related Reactions in Lymphoid Malignancies
03/31/2025
Janelle Bradley
A multicenter retrospective study found that over half of patients receiving obinutuzumab experienced infusion-related reactions, with higher risk observed in those with chronic lymphocytic leukemia or elevated baseline lymphocyte counts.
A multicenter retrospective study found that over half of patients receiving obinutuzumab experienced infusion-related reactions, with higher risk observed in those with chronic lymphocytic leukemia or elevated baseline lymphocyte counts.
A multicenter retrospective...
03/31/2025
APP Institute Oncology
Case Presentation: Gastrointestinal Stromal Tumor
News
PRO-CTCAE Tool Improves Symptom Management in Head and Neck Oncology Clinic
03/28/2025
Janelle Bradley
Implementation of the PRO-CTCAE tool in a head and neck oncology clinic improved symptom identification, documentation, and patient-provider communication without disrupting clinic workflow.
Implementation of the PRO-CTCAE tool in a head and neck oncology clinic improved symptom identification, documentation, and patient-provider communication without disrupting clinic workflow.
Implementation of the PRO-CTCAE...
03/28/2025
APP Institute Oncology
News
Onboarding Tool Improves Gastrointestinal Surgical Oncology APP Integration and Reduces Stress
03/26/2025
Janelle Bradley
A structured onboarding tool for gastrointestinal surgical oncology advanced practice providers improved clinical knowledge, confidence, and reduced perceived stress, facilitating faster progression to independent practice.
A structured onboarding tool for gastrointestinal surgical oncology advanced practice providers improved clinical knowledge, confidence, and reduced perceived stress, facilitating faster progression to independent practice.
A structured onboarding tool for...
03/26/2025
APP Institute Oncology
News
Durvalumab Plus Radiotherapy Fails to Improve Survival Outcomes for Cisplatin-Ineligible Patients With Head and Neck Squamous Cell Carcinoma
12/03/2024
Stephanie Holland
Results from the phase 2/3 NRG-HN004 study demonstrated that durvalumab plus radiotherapy failed to improve survival outcomes compared to cetuximab plus radiotherapy among patients with locoregionally advanced head and neck squamous cell...
Results from the phase 2/3 NRG-HN004 study demonstrated that durvalumab plus radiotherapy failed to improve survival outcomes compared to cetuximab plus radiotherapy among patients with locoregionally advanced head and neck squamous cell...
Results from the phase 2/3...
12/03/2024
APP Institute Oncology

APP Perspectives

Lorinda Coombs
APP Perspectives
Myeloma Care: Patient and Advanced Practice Provider Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
APP Institute Oncology

Conference Coverage

Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Conference Coverage
Biological Pathways Underlying Cancer-Related Cognitive Impairment and Anxiety in Patients Receiving Chemotherapy
04/10/2025
Janelle Bradley
A new study has identified both shared and distinct biological mechanisms underlying cancer-related cognitive impairment and anxiety in patients undergoing chemotherapy.
A new study has identified both shared and distinct biological mechanisms underlying cancer-related cognitive impairment and anxiety in patients undergoing chemotherapy.
A new study has identified both...
04/10/2025
APP Institute Oncology
Conference Coverage
Epigenetic Insights Reveal Distinct Pathways Underlying Cognitive Function in Patients With Early-Stage Breast Cancer
04/10/2025
Janelle Bradley
Epigenetic analysis in postmenopausal women with early-stage breast cancer reveals distinct biological pathways—axonal guidance and synaptogenesis—underlying objective and subjective cognitive function, suggesting separate mechanisms driving...
Epigenetic analysis in postmenopausal women with early-stage breast cancer reveals distinct biological pathways—axonal guidance and synaptogenesis—underlying objective and subjective cognitive function, suggesting separate mechanisms driving...
Epigenetic analysis in...
04/10/2025
APP Institute Oncology
Conference Coverage
Barriers and Drivers of Symptom Self-Management in Rural Cancer Survivors
04/10/2025
Janelle Bradley
Study defines factors that shape rural cancer survivors’ use of symptom self-management strategies, including credibility, symptom severity, accessibility, personal preferences, and social support.
Study defines factors that shape rural cancer survivors’ use of symptom self-management strategies, including credibility, symptom severity, accessibility, personal preferences, and social support.
Study defines factors that shape...
04/10/2025
APP Institute Oncology
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP
Conference Coverage
Oncology Paired Preceptor Program Supports Nurse Practitioner Transition to Practice in Hawaii
11/27/2024
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, assesses the effect implementing an academic-community partnership has on doctor of nursing students who are interested in oncology.
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, assesses the effect implementing an academic-community partnership has on doctor of nursing students who are interested in oncology.
Christa Braun-Inglis, DNP, APRN,...
11/27/2024
APP Institute Oncology
Conference Coverage
Advanced Practice Providers Play Pivotal Role in Delivering Cancer Screening Services and Follow-Up Care to Vulnerable Populations
11/21/2024
Gina Tomaine
Advanced practice providers play a unique role in delivering cancer screening services and follow-up care to vulnerable populations, emphasizing the importance of their expertise, accessibility, and patient-centered approach to improving...
Advanced practice providers play a unique role in delivering cancer screening services and follow-up care to vulnerable populations, emphasizing the importance of their expertise, accessibility, and patient-centered approach to improving...
Advanced practice providers play...
11/21/2024
APP Institute Oncology
Dylana Smith, MS, AGPCNP-BC, HNP
Conference Coverage
Boosting Advanced Practice Provider Engagement at Memorial Sloan Kettering Cancer Center
11/21/2024
Dylana Smith, MS, AGPCNP-BC, HNP, discusses an initiative to boost APP engagement at Memorial Sloan Kettering Cancer Center and the growth of the program since its inception.
Dylana Smith, MS, AGPCNP-BC, HNP, discusses an initiative to boost APP engagement at Memorial Sloan Kettering Cancer Center and the growth of the program since its inception.
Dylana Smith, MS, AGPCNP-BC,...
11/21/2024
APP Institute Oncology
Marlee Bogema, MSN, APRN, FNP-C
Conference Coverage
Outpatient Bispecific Program Demonstrates Safety and Tolerability in the Community Setting
11/21/2024
Marlee Bogema, MSN, APRN, FNP-C, discusses a protocol developed by a community oncology practice which demonstrated that outpatient administration of bispecific antibodies is both safe and well-tolerated and reduces the number of required...
Marlee Bogema, MSN, APRN, FNP-C, discusses a protocol developed by a community oncology practice which demonstrated that outpatient administration of bispecific antibodies is both safe and well-tolerated and reduces the number of required...
Marlee Bogema, MSN, APRN, FNP-C,...
11/21/2024
APP Institute Oncology
Conference Coverage
Amivantamab Plus Chemotherapy Prolongs Survival, Post-Progression Outcomes for Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
11/20/2024
Stephanie Holland
According to second interim analysis results from the MARIPOSA-2 trial, amivantamab plus chemotherapy improved survival and post-progression outcomes compared to chemotherapy alone among patients with EGFR-mutated advanced non-small cell lung...
According to second interim analysis results from the MARIPOSA-2 trial, amivantamab plus chemotherapy improved survival and post-progression outcomes compared to chemotherapy alone among patients with EGFR-mutated advanced non-small cell lung...
According to second interim...
11/20/2024
APP Institute Oncology
Conference Coverage
The Enduring Benefit of Abemaciclib Plus Endocrine Therapy for Patients With HR-Positive, HER2-Negative High-Risk, Early Breast Cancer
11/20/2024
Allison Casey
According to the preplanned overall survival interim analysis from the phase 3 monarchE trial, abemaciclib plus endocrine therapy continues to show benefit for patients with HR-positive, HER2-negative high-risk early breast cancer.
According to the preplanned overall survival interim analysis from the phase 3 monarchE trial, abemaciclib plus endocrine therapy continues to show benefit for patients with HR-positive, HER2-negative high-risk early breast cancer.
According to the preplanned...
11/20/2024
APP Institute Oncology
Conference Coverage
Implementation of an IV Push Policy for Antibiotic Administration Within An Oncology Urgent Care Clinic
11/18/2024
Allison Casey
Introduction of an IV push policy at an oncology urgent care clinic, led by an advanced practice provider, resulted in increased timely administration of antibiotics prior to hospitalization and a decrease in room dwell time.
Introduction of an IV push policy at an oncology urgent care clinic, led by an advanced practice provider, resulted in increased timely administration of antibiotics prior to hospitalization and a decrease in room dwell time.
Introduction of an IV push...
11/18/2024
APP Institute Oncology
APP Institute Oncology

 

The Advanced Practice Provider (APP) Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use